

## **REMARKS/ARGUMENTS**

### **Restriction Requirement**

The Examiner has required restriction to one of the following inventions:

Group I        Claims 1-8, drawn to an isolated nucleic acid, a vector containing same, a host cell thereof, and a method of recombinantly producing the encoded polypeptide.

Group II        Claims 9-11 and 14-17 in part, drawn to an isolated polypeptide, a chimeric molecule thereof, an agonist thereof, and a composition and an article thereof.

Group III       Claims 12, 13, and 14-17 in part, drawn to an antibody to the polypeptide, and a composition and an article thereof.

Group IV        Claims 14-17, drawn to an antagonist of the polypeptide, and a composition and an article thereof.

Group V        Claim 18 in part, drawn to a method of treating psoriasis by administering the polypeptide.

Group VI        Claim 18 in part, drawn to a method of treating psoriasis by administering an antagonist of the polypeptide.

Group VII       Claim 18 in part, drawn to a method of treating psoriasis by administering an antibody of the polypeptide.

Group VIII     Claims 19 and 21, drawn to a method of determining the presence of a PRO polypeptide in a sample, and a method of diagnosing psoriasis with an antibody.

Group IX        Claim 20, drawn to a method of diagnosing psoriasis by detecting the level of expression of a gene encoding the polypeptide.

Group X        Claim 22, drawn to a method of identifying a compound inhibiting the activity of the polypeptide.

Group XI        Claims 23 and 24, drawn to a method of identifying a compound inhibiting the expression of a gene encoding the polypeptide, wherein said candidate compound is an anti-sense nucleic acid.

Group XII       Claim 25, drawn to a method of identifying a compound mimicking the activity of the polypeptide.

The Examiner has also required that a SEQ ID NO: be elected.

Applicants elect Group III, Claims 12, 13, and 14-17 in part, drawn to an antibody to the polypeptide, and a composition and an article thereof. Applicants further elect SEQ ID NO:14 (PRO2874), which is encoded by SEQ ID NO:13 (DNA327522) for the elected claims.

### **CONCLUSION**

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned agent at the telephone number shown below.

Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39766-0263 R1). Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully Submitted,

Date: November 13, 2007

By: \_\_\_\_\_

Panpan Gao (Reg. No. 43,626)

**HELLER EHRMAN LLP**  
275 Middlefield Road  
Menlo Park, California 94025  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 2315880 v1  
(39766.0263)